Wuhan Hiteck Biological Pharma Co.,Ltd agreed to acquire additional 6.9416% stake in Beijing Shadong Biotechnology Co., Ltd. from Beijing Zhongguancun VC Development Co., Ltd.
November 14, 2021
Share
Wuhan Hiteck Biological Pharma Co.,Ltd (SZSE:300683) agreed to acquire additional 6.9416% stake in Beijing Shadong Biotechnology Co., Ltd. from Beijing Zhongguancun VC Development Co., Ltd. on November 11, 2021. As on September 30, 2021, Beijing Shadong Biotechnology Co., Ltd. generated total assets of CNY 3.6 million and net liabilities of CNY 138.9 million. The transaction is approved by board of directors of Wuhan Hiteck Biological Pharma Co.,Ltd.
Wuhan Hiteck Biological Pharma Co Ltd is a biopharmaceutical company. The Company operates five segments. The Biopharmaceutical segment is engaged in research, development, production and sales of biological products, and its primary product is mouse nerve growth factor for injection named Jinlujie. The Medical Technology Service segment is mainly involved in the technical development, technical consultation and technology transfer of chemical drugs. The In Vitro Diagnostic Reagents segment operates the research, development, production and sales of in vitro diagnostic reagents. The Pharmaceutical Sales and Wholesale segment is engaged in the sales and wholesale of pharmaceuticals. The Other segmentâs businesses include the cultivation and sales of Chinese herbal medicines, and the wholesale and retail of health products.
WUHAN HITECK BIOLOGICAL PHARMA CO.,LTD 
